The medical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s exhibiting significant potential in clinical trials for addressing obesity. Unlike some available weight loss approaches, retatrutide appears to provide a significant substantial decrease in body size and enhance metabolic markers,